---
title: "301263.SZ (301263.SZ) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/301263.SZ/news.md"
symbol: "301263.SZ"
name: "301263.SZ"
parent: "https://longbridge.com/zh-HK/quote/301263.SZ.md"
datetime: "2026-03-11T12:30:02.227Z"
locales:
  - [en](https://longbridge.com/en/quote/301263.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301263.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301263.SZ/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/301263.SZ/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/301263.SZ/news.md)


# 301263.SZ (301263.SZ) — 相關新聞

### [Taikang Xianlin Gulou Hospital has been rated as a national Class III Grade A general hospital, accelerating the construction of longevity medical care](https://longbridge.com/zh-HK/news/277762053.md)
*2026-03-04T10:20:21.000Z*
> The Jiangsu Provincial Health and Health Commission announced the evaluation results of tertiary hospitals for 2025. Nan

### [T&K: Wholly-owned subsidiary selected for the continuation procurement of certain drugs in the national centralized procurement of medicines](https://longbridge.com/zh-HK/news/277431616.md)
*2026-03-02T08:42:32.000Z*
> T&K announced that its wholly-owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. participated in the biddi

### [T&K: Wholly-owned subsidiary receives Minoxidil topical solution drug registration certificate](https://longbridge.com/zh-HK/news/275094983.md)
*2026-02-06T08:21:30.000Z*
> T&K announced that its wholly-owned subsidiary Huabo Kaisheng recently received the Minoxidil topical solution "Drug Reg

### [T&K: Wholly-owned subsidiary receives drug registration certificate for Nimodipine Injection](https://longbridge.com/zh-HK/news/274270951.md)
*2026-01-30T08:11:35.000Z*
> T&K announced that its wholly-owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. recently received the Dru

### [T&K: Expected net profit to decline by 67.66%-76.90% year-on-year in 2025](https://longbridge.com/zh-HK/news/273977472.md)
*2026-01-28T10:54:42.000Z*
> T&K expects a net profit of 25 million to 35 million yuan in 2025, a year-on-year decrease of 67.66% to 76.90%. The core

### [T&K: The holding subsidiary CKBA's cream for children's vitiligo has received approval for clinical trials](https://longbridge.com/zh-HK/news/273371042.md)
*2026-01-22T12:20:12.000Z*
> T&K announced that its holding subsidiary, Jiangsu Bochuangyuan Biomedical Technology Co., Ltd., has received the "Drug 

### ["A-Share Focus" The drug regulatory authority optimizes the approval process for urgently needed overseas listed drugs, innovative drug concept stocks are strong](https://longbridge.com/zh-HK/news/271867760.md)
*2026-01-08T02:33:00.000Z*
> The National Medical Products Administration has optimized the approval process for overseas listed drugs, encouraging t

### [T&K: Appointed Zheng Ruihan and Lin Zili as the company's deputy general managers](https://longbridge.com/zh-HK/news/270834186.md)
*2025-12-26T08:44:03.000Z*
> On December 26th, T&K announced that the twelfth meeting of the fifth board of directors reviewed and approved the propo

### [T&K's subsidiary received the registration certificate for Finasteride and Tadalafil capsules](https://longbridge.com/zh-HK/news/270496108.md)
*2025-12-22T13:10:04.000Z*
> T&K's wholly-owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. has obtained the drug registration certifi

### [T&K: The application for the registration and listing permit of Indobufen tablets for domestic production has been accepted](https://longbridge.com/zh-HK/news/269061250.md)
*2025-12-09T09:19:03.000Z*
> T&K announced that the application for the domestic production drug registration and marketing authorization of Indobufe